Screener
Dyne Therapeutics, Inc. DYN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of marketable securities | (64,278) | (65,970) |
| Maturities of marketable securities | 33,459 | 65,439 |
| Sales of marketable securities | 28,648 | 2,970 |
| Net cash used in investing activities | (2,392) | 1,458 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 1,311 | 588 |
| Payment of debt issuance costs | (30) | — |
| Payment of issuance costs from public offering of common stock | (424) | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s investing cash flow?
- Dyne Therapeutics, Inc. (DYN) reported investing cash flow of -$2.39M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Dyne Therapeutics, Inc.'s investing cash flow decreased by 264.1% year-over-year, from $1.46M to -$2.39M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s investing cash flow?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s investing cash flow has grown at a -31.9% compound annual growth rate (CAGR), from -$137.89M to -$29.73M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Dyne Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude